CN Patent

CN117396208A — 细胞周期蛋白依赖性激酶4/6(cdk4/6)和ikzf2(helios)的小分子降解剂及其使用方法

Assigned to Dana Farber Cancer Institute Inc · Expires 2024-01-12 · 2y expired

What this patent protects

本申请提供了双功能化合物，其作为细胞周期蛋白依赖性激酶4(CDK4)、细胞周期蛋白依赖性激酶6(CDK6)和Ikaros家族锌指2(IKZF2)(也称为Helios)的诱导蛋白降解部分。还公开了用于治疗受CDK4、CDK6和IKZF2调节的病症的方法。

USPTO Abstract

本申请提供了双功能化合物，其作为细胞周期蛋白依赖性激酶4(CDK4)、细胞周期蛋白依赖性激酶6(CDK6)和Ikaros家族锌指2(IKZF2)(也称为Helios)的诱导蛋白降解部分。还公开了用于治疗受CDK4、CDK6和IKZF2调节的病症的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN117396208A
Jurisdiction
CN
Classification
—
Expires
2024-01-12
Drug substance claim
No
Drug product claim
No
Assignee
Dana Farber Cancer Institute Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.